Journal of Diabetes Research

Glucagon-Like Peptide-1 and Diabetes


Publishing date
01 Jul 2011
Status
Published
Submission deadline
01 Jan 2011

1Section of Geriatric Cardiology and Medicine, Department of Cardiovascular Medicine, University of Florence and Diabetes Section, Careggi Teaching Hospital, Florence, 50141, Italy

2Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 21250, USA

3Diabetes Agency, Careggi Teaching Hospital, 50141 Florence, Italy

4Section of Endocrinology, Department of Clinical Pathophysiology, University of Florence and Careggi University Hospital, 50141 Florence, Italy


Glucagon-Like Peptide-1 and Diabetes

Description

The gastrointestinal hormone glucagon-like peptide-1 (GLP-1), which is mainly secreted after meals, enhances glucose-stimulated insulin release and inhibits food intake. The response of circulating active GLP-1 concentrations after a standard meal, as well as after an oral glucose load, has been reported to be reduced in type 2 diabetic patients in comparison with healthy subjects. Available data suggest that GLP-1 plays a relevant role in the regulation of postprandial glucose metabolism in physiologic conditions. Furthermore, the impairment of GLP-1 secretion after meals could contribute to the pathogenesis of hyperglycemia in type 2 diabetes. Several new drugs act through the GLP-1 signaling system to stimulate insulin release and regulate blood glucose levels in patients with diabetes.

We invite investigators to contribute original research articles as well as review articles that will stimulate the continuing efforts to understand the physiologic role, biologic action, and therapeutic properties of incretins and incretin-based therapies. Potential topics include, but are not limited to:

  • Recent developments in physiology of GLP-1
  • Biology of GLP-1 recent development at the experimental level
  • Advances in therapeutic potential of GLP-1 agents
  • Effects of incretin-based therapies in delaying/halting the progression of diabetes
  • Potential beneficial/detrimental actions on the cardiovascular system (or others)

Considering the aims of the journal, experimental studies will be particularly welcome, as well as mechanistic studies exploring special aspects of GLP-1-related therapies, with particular regard to the cardiovascular system and to micro vascular complications of diabetes. Novel data on DPP-4 inhibition, with a special focus on the possible effects of DPP-4 other than GLP-1 and GIP degradation, would also be welcome.

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.hindawi.com/journals/jdr/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/ according to the following timetable:


Articles

  • Special Issue
  • - Volume 2011
  • - Article ID 901954
  • - Editorial

Glucagon-Like Peptide-1 and Diabetes

Matteo Monami
  • Special Issue
  • - Volume 2011
  • - Article ID 898913
  • - Review Article

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Ilaria Dicembrini | Laura Pala | Carlo Maria Rotella
  • Special Issue
  • - Volume 2011
  • - Article ID 279530
  • - Review Article

Effects of GLP-1 and Incretin-Based Therapies on Gastrointestinal Motor Function

Chinmay S. Marathe | Christopher K. Rayner | ... | Michael Horowitz
  • Special Issue
  • - Volume 2011
  • - Article ID 601047
  • - Review Article

Glucagon-Like Peptide-1 Gene Therapy

Anne M. Rowzee | Niamh X. Cawley | ... | Giovanni Di Pasquale
  • Special Issue
  • - Volume 2011
  • - Article ID 489708
  • - Research Article

Assessment of Glucagon-Like Peptide-1 Analogue and Renin Inhibitor on the Binding and Regulation of GLP-1 Receptor in Type 1 Diabetic Rat Hearts

Shushan B. Artinian | Sawsan M. Al Lafi | ... | Anwar B. Bikhazi
  • Special Issue
  • - Volume 2011
  • - Article ID 281674
  • - Review Article

Glucagon-Like Peptide-1, Diabetes, and Cognitive Decline: Possible Pathophysiological Links and Therapeutic Opportunities

Enrico Mossello | Elena Ballini | ... | Niccolò Marchionni
  • Special Issue
  • - Volume 2011
  • - Article ID 376509
  • - Review Article

Activation of the GLP-1 Receptor Signalling Pathway: A Relevant Strategy to Repair a Deficient Beta-Cell Mass

Bernard Portha | Cécile Tourrel-Cuzin | Jamileh Movassat
  • Special Issue
  • - Volume 2011
  • - Article ID 215764
  • - Research Article

Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Events: A Meta-Analysis of Randomized Clinical Trials

Matteo Monami | Francesco Cremasco | ... | Edoardo Mannucci
  • Special Issue
  • - Volume 2011
  • - Article ID 319202
  • - Erratum

Erratum to “Subthreshold α2-Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion”

Minglin Pan | Guang Yang | ... | Shao-Nian Yang
  • Special Issue
  • - Volume 2011
  • - Article ID 604989
  • - Research Article

Subthreshold α2-Adrenergic Activation Counteracts Glucagon-Like Peptide-1 Potentiation of Glucose-Stimulated Insulin Secretion

Minglin Pan | Guang Yang | ... | Shao-Nian Yang
Journal of Diabetes Research
 Journal metrics
Acceptance rate31%
Submission to final decision73 days
Acceptance to publication25 days
CiteScore3.020
Impact Factor3.040
 Submit

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.